[Brief treatment with thymopentin as adjuvant in vaccination for hepatitis B: controlled study in patients on periodic hemodialysis].
Eleven hemodialysis patients (9 M, 2 F, aged 65 +/- 20 yrs) (Group A) were treated with thymopentin (TP-5) 50 mg as adjuvant therapy to HB vaccination, with 3 weekly administrations, the week before and the two following the first dose of Pasteur vaccine, 5 micrograms. The percentage of patients developing a sufficient antibody titer (20 mUI/ml) after 4 vaccine doses was not statistically different from that obtained among control groups B and C. The age- and sex- matched controls received the same vaccine schedule without adjuvant. The percentages were as follows: Group A 54.5%, Group B 63.6%, Group C 60%. No local or systemic side effects were encountered after the TP-5 administration. The authors suggest that a short TP-5 treatment as an adjuvant therapy to HB vaccination is not effective in patients maintained on hemodialysis.
Palestini
M
M
Istituto di Clinica Chirurgica, Università degli studi La Sapienza, Roma.
Messina
A
A
Ciaraffo
F
F
De Sanctis
G M
GM
Errera
G
G
Corradini
S G
SG
D000276:Adjuvants, Immunologic; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D016305:Thymopentin / Q000627:therapeutic use*; D014611:Vaccination
D000276:Adjuvants, Immunologic; D016305:Thymopentin
Trattamento breve con timopentina come adiuvante nella vaccinazione anti-epatite B: studio controllato in pazienti sottoposti ad emodialisi periodica.